Navigation Links
Double-therapy approach effectively inhibited brain cancer recurrence

PHILADELPHIA Researchers from the University of Massachusetts Medical School have identified a novel approach of combining chemotherapy with a targeted therapy to decrease the recurrence of glioblastoma multiforme, the most common and aggressive brain tumor.

"Glioblastomas are horrendous tumors, and new therapies are desperately needed," said lead researcher Alonzo H. Ross, Ph.D., professor of biochemistry and molecular pharmacology at the University of Massachusetts Medical School.

"We found that this double therapy of combining temozolomide with a Notch inhibitor was highly effective at treating tumor cells in culture and in mice," he added.

Results of this study are published in the September issue of Cancer Research, a journal of the American Association for Cancer Research.

Despite treatment with surgery, radiotherapy and chemotherapy, glioblastoma prognosis and survival rates are poor. This may in part be due to the fact that some cells within the tumor cancer stem cells are more resistant to these therapies, eventually allowing the tumor to recur, according to Ross.

"We're both very successful and unsuccessful with cancer therapy; in most cases we can substantially diminish the tumor mass. The problem is that it comes back with vengeance, and is even more resistant and difficult to treat," he said.

Temozolomide is one chemotherapeutic agent that helps patients with glioblastomas live longer; two-year survival rates increase from approximately 10 percent with radiation alone to 25 percent when temozolomide is combined with radiation, according to Ross. Likewise, data have indicated that the Notch signaling pathway is often over-expressed in glioma tissue and tumor cells.

Ross and colleagues evaluated this double-therapy approach of combining temozolomide with a Notch inhibitor in cell culture and in immunodeficient mice to determine if this combination therapy enhances therapy to reduce tumor recurrence.

In both models, the researchers saw that the combination of temozolomide with the Notch inhibitor much more effectively reduced tumor growth and recurrence compared to either agent alone. Either drug used individually only transiently slowed tumor growth.

"Temozolomide is a chemotherapy drug of choice for glioblastomas, and the results of our preclinical study represent a potential promising new approach to combat an extremely difficult tumor," Ross said. "The effect of the two together is very dramatic."

Patrick M. O'Connor, Ph.D., chief scientific officer of Selexagen Therapeutics and editorial board member for Cancer Research, believes this study provides preclinical proof-of-concept evidence that the Notch pathway confers a survival advantage to glioma cells treated with temozolamide.

"These results help lay the groundwork for future clinical research and are yet another stepping stone towards a future era dominated by 'precision therapeutics' designed to specifically target the underlying molecular drivers of cancer growth and spread," said O'Connor.

The researchers are currently investigating the mechanism of action for cell death and hope to move these findings into the clinic.


Contact: Tara Yates
American Association for Cancer Research

Related medicine news :

1. Survival benefit with high-intensity end-of-life approaches
2. Mountain Home 'Doing the Right Thing Really is the Best Business Approach'
3. ICU Patients Gain From Team Approach to Care
4. Short on specialized intensive care physicians, team-based approach improves ICU outcomes
5. Lumension Unveils Intelligent Application Whitelisting that Operationalizes a Proactive Endpoint Security Approach
6. Secretary Clintons Approach to Development: Good Rhetoric, Little Action?
7. New Approaches to Teen Therapy Bring Results
8. New Drugs, Approaches Offer Hope Against Prostate Cancer
9. New approach to immune cell analysis seen as first step to better distinguish health and disease
10. Reovirus may be a novel approach to prostate cancer treatment
11. Effort aims to spike breast cancer with new approach
Post Your Comments:
Related Image:
Double-therapy approach effectively inhibited brain cancer recurrence
(Date:12/1/2015)... ... ... The Multiple System Atrophy Coalition has announced the launch of its MSA Can’t ... today to coincide with Giving Tuesday 2015, a global day of fundraising. , ... be productive, to do simple daily activities like walking to the mailbox and eating ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Royal River ... a new study that found post-menopausal women who took the nutritional supplement creatine, along ... women who trained but did not take creatine. , The report is part of ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... leadless pacemakers in the U.S. and is the only hospital in the region ... largest clinical data presentation of transcatheter pacing patients were revealed recently at a ...
(Date:12/1/2015)... ... 01, 2015 , ... December 1, 2015 -- InstantLabs is ... growing product line of food safety and seafood fraud prevention tools. , The ... allow InstantLabs to offer fast, reliable species identification for the four most popular ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... A federal court has denied the state of ... filed by the Pharmaceutical Care Management Association (PCMA) challenging the ... law that forces employers and consumers to pay drugstores higher ... must now defend a law that raises health care ... Mark Merritt . --> Arkansas ...
(Date:12/1/2015)... 1, 2015 Pharma Tech Outlook recently conducted ... Clinical Data Management Solution Providers - 2015 .  After ... comprising CEOs, CIOs, VCs, analysts, and the Pharma Tech ... of top 10 clinical data management solution providers (check ... 14 and 36 respectively). --> ...
(Date:12/1/2015)... VERONA, Va. , Dec. 1, 2015 /PRNewswire/ ... today unveiled a new corporate logo and brand ... in the design and engineering of bladed products ... --> --> Serving ... fiber, glass, and auto glass equipment, AccuTEC,s product ...
Breaking Medicine Technology: